Premier Biomedical, Inc.
BIEI
$0.0004
-$0.0002-33.33%
| 12/31/2019 | 09/30/2019 | 06/30/2019 | 03/31/2019 | 12/31/2018 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -56.98% | -30.08% | 0.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -56.98% | -30.08% | 0.00% |
| Cost of Revenue | -- | -- | 143.41% | 247.47% | 346.27% |
| Gross Profit | -- | -- | -463.41% | -501.08% | -617.48% |
| SG&A Expenses | -- | -- | -44.03% | -43.67% | -44.73% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -- | -45.92% | -44.56% | -44.89% |
| Operating Income | -- | -- | 45.40% | 45.14% | 46.29% |
| Income Before Tax | -- | -- | -131.22% | -142.06% | 89.40% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -- | -- | -131.22% | -142.06% | 89.40% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | -131.22% | -142.06% | 89.40% |
| EBIT | -- | -- | 45.40% | 45.14% | 46.29% |
| EBITDA | -- | -- | 45.49% | 45.22% | 46.37% |
| EPS Basic | -- | -- | -114.21% | -123.62% | 98.01% |
| Normalized Basic EPS | -- | -- | -114.29% | -123.74% | 97.95% |
| EPS Diluted | -- | -- | -114.33% | -123.94% | 98.02% |
| Normalized Diluted EPS | -- | -- | -114.39% | -124.02% | 97.92% |
| Average Basic Shares Outstanding | -- | -- | 154.27% | 102.54% | 79.01% |
| Average Diluted Shares Outstanding | -- | -- | 153.67% | 102.01% | 78.80% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
